Education
About Us
Working with TipRanks
Follow Us
SciBase Holding AB (DE:5J3)
FRANKFURT:5J3
5J3 Stock Chart & Stats
€0.04
<€0.01(5.00%)
At close: 4:00 PM EST
€0.04
<€0.01(5.00%)
Day’s Range― - ―
52-Week Range€0.00 - €0.04
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€23.34M
Enterprise Value€101.92M
Total Cash (Recent Filing)€22.60M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta7.11
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding828,365,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€6.27M
Bulls Say, Bears Say
Bulls Say
Strong Multi‑year Revenue Growth & High Gross MarginConsistent multi‑year revenue growth to 40.5M with ~67% gross margin indicates real commercial traction for Nevisense. High gross margins support operating leverage as installed base and consumable pull‑through scale, giving a durable foundation for future profitability if opex is controlled.
Low Financial Leverage (minimal Debt)Near‑zero reported debt reduces fixed financing obligations and interest burden, improving financial flexibility. This lower leverage preserves strategic optionality to fund commercialization or regulatory programs without immediate refinancing stress, a structurally positive position during growth phases.
Recurring Consumables & Service Revenue ModelA business model driven by system sales plus recurring consumables and services creates predictable, scalable revenue as the installed base grows. Consumable pull‑through and service contracts build sticky customer relationships and recurring cash flows, supporting long‑term margin sustainability.
Bears Say
Deep And Worsening Operating Cash BurnVery large negative operating cash flow that worsened materially in 2025 signals heavy ongoing cash consumption. Structurally, this raises reliance on external financing, increases dilution risk, and could force cutbacks to commercial or R&D programs if additional capital is constrained over the next several months.
Sharply Weakened Equity / Compressed Balance SheetA large decline in equity and shrinking asset base materially reduces the balance‑sheet buffer against shocks. This weakened capital position limits strategic flexibility, heightens funding vulnerability, and increases the probability of dilutive equity raises or constrained investment in commercialization or regulatory milestones.
Large And Widening Operating LossesDespite top‑line momentum and healthy gross margins, escalating operating losses show cost base growth outpacing revenue. Persistently widening losses indicate a weak path to operating leverage and raise questions about long‑term profitability unless spending is reined in or revenue accelerates substantially.
SciBase Holding AB News
5J3 FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was €0.00 and its highest was €0.04 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is €23.34M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is May 07, 2026 which is in 51 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on Mar 13, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 828,365,200 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in DE:5J3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology company, develops and sells instruments for the detection of skin cancer and other skin conditions in Europe and internationally. Its product includes Nevisense and Nevisense Go, a point of care platform that addresses in the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. The company has a collaboration agreement with Advanced Dermatology and Cosmetic Surgery (ADCS) group. SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―